Valeant gets additional notices of default from bondholders
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/8/2026
- S&P 500, Nasdaq futures climb as chip stocks stabilize
- Oil prices climb more than $4 after Israeli strikes on Iran and Lebanon
- U.S. economy adds 172,000 jobs in May, topping expectations
- Citi warns global stock markets are the frothiest since 2008
- JPMorgan upgrades Tesla, sets new price target on robotaxi and Optimus potential
- Earthquake of magnitude 7.8 strikes off southern Philippines, 32 feared dead
- Wall Street ends sharply lower as chips slide, jobs data fuels rate hike fears
- Marvell Technology and Flex to join S&P 500; others to join S&P MidCap 400 and S&P SmallCap 600
- SpaceX signs $920 million monthly cloud deal with Google
- Target recalls Up & Up baby wipes due to bacterial contamination
Valeant Pharma (VRX) Appoints Joseph Papa as CEO
April 25, 2016 8:38 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that its Board of Directors has named Joseph C. Papa to become Valeant's Chairman and Chief Executive Officer. Mr. Papa is expected to join Valeant by early May. Mr. Papa will join Valeant from Perrigo Company plc, a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, where he served as Chairman and Chief Executive Officer. Mr. Papa, who will also join Valeant's Board of Directors, will succeed J. Michael Pearson, who is expected to remain as CEO and a... More
Valeant Pharma (VRX) Announces Receipt of Additional Notice of Default Due to Delay of 10-K Filing
April 25, 2016 6:28 AM EDTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced that, as a result of the delay in the Company filing its Form 10-K for the fiscal year ended December 31, 2015 (the "Form 10-K"), it has received notices of default from the trustee under the indentures governing its 5.375% Senior Notes due... More
